Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.
Published: Feb 19, 2021 By Gail Dutton
The skills gap in cell and gene therapy is creating a bottleneck that is slowing the abilities of innovative therapies to reach patients, delaying manufacturing scaleup and increasing learning and development costs.
“The shortage runs across every functional team, at every level,” Anshul Mangal, president,
What’s different about cell and gene therapy – versus biologics, for example – is the newness of the field.
“Cell and gene therapy is very personalized…very innovative,” he said.
There’s great expertise in R&D, but few cell and gene therapies have reached commercial scale. Therefore, cell and gene therapies have fewer experienced personnel available with experience in scaling-up.
Precision Medicine Group Significantly Expands Cell And Gene Therapy Expertise With Acquisition Of Project Farma
News provided by
Share this article
Share this article
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION S CELL AND GENE THERAPY OFFERING PRECISION ADVANCE ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
BETHESDA, Md., Jan. 14, 2021 /PRNewswire/ Precision Medicine Group ( PMG ) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma s unique expertise to Precision s suite of end-to-end cell and gene therapy capabilit
14 gennaio 2021 09:11
Fonte: Adnkronos
#salute-e-benessere
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION S CELL AND GENE THERAPY OFFERING PRECISION ADVANCE ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
BETHESDA, Md., Jan. 14, 2021 /PRNewswire/ Precision Medicine Group ( PMG ) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma s unique expertise to Precision s suite of end-to-end cell and gene therapy capabilities to support development and commercialization.
Precision Medicine Group Significantly Expands Cell And Gene Therapy Expertise
BETHESDA, Md., Jan. 14. /PRNewswire/. Precision Medicine Group ( PMG ) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma s unique expertise to Precision s suite of end-to-end cell and gene therapy capabilities to support development and commercialization.
Led by executive leaders Anshul Mangal, John Khoury, and Tony Khoury, Project Farma has distinguished itself as a global leader in planning and implementing complex biomanufacturing strategies and facilities for clients that range from start-up biotechnology companies to global biopharmaceutical compa